SCHOTT Pharma (1SXP) Q4 2025 earnings summary

Executive summary

• Achieved full-year revenue and profitability targets for FY 2025, with high-value solutions (HVS) reaching 57% of revenues and continued global expansion and innovation.

• Significant progress in expanding production capacities and launching new products, supporting innovation leadership.

• Leadership transition: Christian Meisel (or Mias) appointed CEO from May 2026, Reinhard Mayer as CFO from August 2025.

Financial highlights

• FY 2025 revenues reached EUR 986 million, up 3% year-over-year (5.8% at constant currencies), with EBITDA margin at 28.4%.

• EBIT grew by 4.3% to EUR 201 million; EPS was EUR 0.97, slightly down from EUR 0.99.

• Dividend proposal increased to EUR 0.18 per share, marking the third consecutive rise since IPO.

• Free cash flow for the year was EUR 37 million, impacted by higher working capital and tax payments.

• Capital expenditure stable at EUR 145 million, focused on HVS capacity and innovation.

Outlook and guidance

• FY 2026 organic revenue growth expected at 2%-5% at constant currencies, with EBITDA margin around 27% due to product mix and ramp-up costs.

• Growth in 2026 to be driven by Drug Containment Solutions (DCS), while Drug Delivery Solutions (DDS) faces lower demand.

• CapEx planned at EUR 140-160 million, focused on HVS capacity and innovation.

• Midterm (2027-2029) revenue CAGR revised to 6%-8%, EBITDA margin to approach 30%.